Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

Status Recruiting

Clinical Trial Summary

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

Clinical Trial Description

Lung transplantation currently is one way to treat a variety of serious diseases and conditions such as emphysema, pulmonary fibrosis, and cystic fibrosis. Ischemia Reperfusion Injury (IRI) is a known problem that can happen during the first few days after a lung transplant. IRI can cause swelling of the lungs and low levels of oxygen. The most serious type of IRI can cause the transplanted lung to not work properly, it can even cause death. While new treatments and practices have been put into place to lower the chances of IRI, it is still a difficult problem to overcome after a lung transplant. Molecule called Adenosine 2A receptor (A2AR) have been studied in animals with IRI for many years. Some of these studies suggest that with the use of A2AR agonist, the chance of IRI may be lowered or prevented. Regadenoson is a selective A2AR agonist. ;

Study Design

Related Conditions & MeSH terms

Lung Transplant

Clinical Trial Details

NCT number	NCT04521569
Study type	Interventional
Source	University of Maryland, Baltimore
Contact	Kaitlyn Masih, BSN
Phone	410-328-4562
Email	kmasih@som.umaryland.edu
Status	Recruiting
Phase	Early Phase 1
Start date	June 22, 2020
Completion date	July 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05404919` - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates	Phase 2
Completed	`NCT03299504` - Factors Predicting Success in Lung Transplant Recipients Who Have Undergone Intensive Post-operative Rehabilitation
Completed	`NCT00755781` - Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation	Phase 3
Recruiting	`NCT05547698` - A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation	N/A
Terminated	`NCT03207399` - Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment	Phase 4
Completed	`NCT03300882` - PREDICT Cytomegalovirus (CMV)
Recruiting	`NCT05101460` - An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
Completed	`NCT03150095` - Health Coaching to Improve Self-Management in Thoracic Transplant Candidates	N/A
Completed	`NCT04420195` - Envarsus XR in Lung Transplant	Phase 2
Recruiting	`NCT02235610` - Use of Ex Vivo Lung Perfusion (EVLP) in Reconditioning Marginal Donor Lungs for Transplantation	N/A
Not yet recruiting	`NCT06066229` - Identification of Patient Important Outcomes in Lung Transplantation
Recruiting	`NCT04601818` - Planned Semi-Elective Lung Tx Study	N/A
Recruiting	`NCT03072589` - Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation	Phase 1
Completed	`NCT01963780` - International EXPAND Lung Pivotal Trial	N/A
Recruiting	`NCT05671887` - DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
Completed	`NCT03987113` - Impact of Cold Ischemia on Pulmonary Endothelial Dysfunction in Ex-vivo Pulmonary Reconditioning
Recruiting	`NCT02748798` - Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders	Early Phase 1
Completed	`NCT03167528` - Contribution of Learning and Practice of Different Complementary Therapies in Pulmonary Transplant Patients	N/A
Active, not recruiting	`NCT04244734` - Implementation of an Early Rehabilitation Program for the Patient With Lung Transplantation: From the ICU to Home.	N/A
Active, not recruiting	`NCT01365429` - Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs	N/A